Semaglutide Protects Kidneys From Obesity-Related Damage in Mice Through Anti-Inflammatory Pathway

What the researchers found

In 48 mice divided into four groups (normal diet, high-fat diet, HFD + semaglutide, HFD + adenosine):

- Semaglutide reduced weight in obese mice

- Improved glucose and lipid metabolism markers

- Reduced inflammation and oxidative stress

- Improved glomerular and tubular kidney lesions (confirmed by light and electron microscopy)

- Proteomics (LC-MS/MS) identified the Txnip/NLRP3 signaling pathway as involved in obesity-related kidney damage

- Western blot confirmed that Txn, Txnip, and NLRP3 protein expression was elevated in obese mice and significantly reduced by semaglutide treatment

- Adenosine showed similar protective effects

Why it matters

Obesity-related kidney disease is a growing global problem as obesity rates increase. Understanding how semaglutide protects the kidneys — beyond just causing weight loss — is important for expanding its therapeutic applications. The identification of the Txnip/NLRP3 inflammasome pathway provides a specific molecular mechanism that could be targeted by future therapies.

How the study worked

Forty-eight mice were divided into four groups: normal-fat diet, high-fat diet (HFD), HFD + semaglutide, and HFD + adenosine. After treatment, serum, urine, and kidney tissue were collected. Assessments included glucose/lipid metabolism markers, inflammatory and oxidative stress markers, kidney damage proteins, and urinary protein/creatinine ratios. Kidney pathology was examined by light and electron microscopy. Total kidney protein differences were analyzed by LC-MS/MS proteomics, with key findings validated by Western blot.

What this study cannot tell us

This was an animal study in mice, and results may not directly translate to humans. The high-fat diet model produces a specific type of obesity that may differ from human obesity patterns. The study could not determine whether kidney protection was a direct effect of semaglutide on the kidneys or an indirect result of weight loss and metabolic improvement. The comparison with adenosine, while interesting, complicates interpretation of semaglutide-specific effects.

How to read the evidence

This is a preclinical mouse study using a high-fat diet model of obesity. While it provides mechanistic insights through proteomics, it represents early-stage evidence that needs validation in human studies.

When this study was published

Published in 2025, this is very recent research adding mechanistic detail to the growing body of evidence supporting semaglutide's kidney-protective effects.

The bigger picture

The NLRP3 inflammasome is increasingly recognized as a key driver of chronic kidney disease across multiple causes. This study adds obesity-related kidney damage to the conditions where semaglutide appears to exert anti-inflammatory kidney protection through inflammasome suppression. Combined with clinical data from the FLOW and SOUL trials, it builds the case for GLP-1 drugs as kidney-protective agents.

Questions still open

• Is semaglutide's kidney protection in obesity primarily due to direct renal effects or indirect metabolic improvement?
• Would targeting the Txnip/NLRP3 pathway directly (without GLP-1 agonism) provide similar kidney protection?
• Do clinical doses of semaglutide in humans achieve the same Txnip/NLRP3 suppression seen in this mouse model?

Common questions

Read the original research

Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.

Diabetology & metabolic syndrome, 17(1), 164

Citation

Wang, Shuqi; Pan, Xiaoyu; Liang, Ruiqing; Chen, Shuchun. (2025). Semaglutide and adenosine alleviate obesity-induced kidney injury, with observed modulation of the Txnip/NLRP3 pathway.. Diabetology & metabolic syndrome, 17(1), 164. https://doi.org/10.1186/s13098-025-01736-2